Who is sponsoring NCT03589053?

NCT03589053 is sponsored by Capital Medical University.

What drugs are being tested in NCT03589053?

Interventions in NCT03589053: Limb remote ischemic conditioning, Control group.

What condition does NCT03589053 study?

NCT03589053 studies Ischemic Cerebrovascular Disease.

Is NCT03589053 still recruiting?

NCT03589053 is currently status unknown. Last updated 9 October 2018.

Last reviewed 2018-10-09 · How we verify

NCT03589053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Limb Remote Ischemic Conditioning and Cerebrovascular Reserve

Status unknown Phase 2 Last updated 9 October 2018

What this trial tests

Phase 2 trial testing Limb remote ischemic conditioning in Ischemic Cerebrovascular Disease in 30 participants. Status unknown.

Timeline

8 October 2018

Primary endpoint
30 December 2018

30 March 2019

Quick facts

Lead sponsor	Capital Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	8 October 2018
Primary completion	30 December 2018
Estimated completion	30 March 2019
Sites	1 location across China

Drugs / interventions tested

Limb remote ischemic conditioning
Control group — full drug profile →

Conditions studied

Ischemic Cerebrovascular Disease — all drugs for Ischemic Cerebrovascular Disease →

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Ischemic Cerebrovascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebrovascular reserve (CVR), defined as the increase in cerebral blood flow (CBF)in response to a vasodilatory stimulus, is known to reflect the compensative capacity of the brain to maintain adequate blood flow in the face of decreased perfusion due to arterial stenosis. CVR dysfunction has been identified as an independent risk factor for ischemic stroke. Limb remote ischemic preconditioning （LRIC) has been suggested as a protective therapeutic modality against brain ischemia. So it is worth to detect whether LRIC can improve the CVR ability in ischemic cerebrovascular disease patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Remote ischaemic conditioning for stroke: unanswered questions and future directions.
Baig S, Moyle B, Nair KPS, Redgrave J, et al · · 2021 · cited 15× · PMID 33903181 · DOI 10.1136/svn-2020-000722

Verify or expand the search:

Other recruiting trials for Ischemic Cerebrovascular Disease

Currently open trials in the same condition.

NCT06978348 — Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology. · recruiting
NCT06890702 — Clinical Evaluation of New Biomarkers for Ischemic Cerebrovascular Disease · recruiting
NCT06001073 — Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03589053 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 9 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03589053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing